01Why study this case — a drug disaster that is not yet over
The drug disasters so far had their causes identified, their regulations changed, and a kind of "ending." The opioid crisis is different. It began in 1996 and, changing form, continues to kill large numbers in the United States every year. It is a drug disaster that is not over.
What makes this crisis distinctive is that its trigger was "sales and marketing." The drug itself is a powerful, useful analgesic when used appropriately. The problem was that powerful opioids were driven to be prescribed in vast quantities on the false premise that "the risk of addiction is low." This piece traces the structure of a crisis in which the corporate sales posture and the limits of regulation and distribution remain in question at the same time.
021996, the launch of OxyContin — the story of "hard to get addicted to"
In 1996, Purdue Pharma launched OxyContin — a controlled-release (slow-acting) formulation of oxycodone, a powerful opioid (narcotic analgesic). The company actively advertised that, because of this controlled release, it carried "a low risk of addiction."
This claim of being "hard to get addicted to" had little solid scientific basis. Even so, through aggressive sales activity — intensive outreach to physicians, sales incentives, and the backing of a trend to treat pain actively as "the fifth vital sign" — OxyContin spread explosively. Powerful opioids, which should be used with caution, came to be prescribed widely for chronic pain in general.
03From addiction to heroin and fentanyl — three waves
As addiction to prescribed opioids spread, the crisis moved to its next stages. U.S. health authorities organize this crisis into three waves.
- First wave (1990s–) — rising addiction and overdose deaths from prescription opioids (OxyContin and others)
- Second wave (2010–) — addicted people, finding prescriptions harder to obtain, shifting to cheaper heroin
- Third wave (2013–) — a surge of deaths from illicitly distributed, powerful synthetic opioids, above all fentanyl
Addiction that began with a single prescribed tablet chained into an epidemic of illicit drugs. The structure of that chain — the marketing of a legal medicine leading, in the end, to mass death from illicit drugs — is what decisively sets this crisis apart from other drug disasters.
04The scale of harm — hundreds of thousands of deaths
Opioid-related overdose deaths in the United States have in recent years reached a level exceeding 80,000 per year. Cumulatively, from the crisis's beginning, the dead number in the hundreds of thousands. This is a public-health catastrophe far surpassing any single earlier drug disaster.
The victims were not illicit-drug users from the start. Many were ordinary patients who fell into addiction starting from opioids prescribed by a doctor for post-surgical pain or chronic back pain. What began as treatment led to addiction and death — there lies the tragedy of this crisis.
05Responsibility still in question — company, regulator, distributor
In the opioid crisis, responsibility at several layers remains in question at once.
- The manufacturer — marketing that made the addiction risk look small. Purdue Pharma pleaded guilty in 2007 to misbranding regarding OxyContin's addictiveness, and enormous settlements and bankruptcy proceedings followed
- The regulator — how far, and when, could the expansion of marketing and prescribing have been stopped? The limits of regulation are in question
- The distributors — the wholesalers' responsibility for overlooking suspiciously large orders
Lawsuits by states and localities followed one after another, and the manufacturing and distribution companies have agreed to settlements totaling tens of billions of dollars. But settlement money does not bring back lost lives. And the crisis itself continues today. Not "the wrongdoing of one company" but a structural failure woven by company, regulator, and distributor — that is the essence of the opioid crisis.
06Four lessons that remain today
Lesson 1 — Marketing has the power to remake the norms of prescribing themselves
The trigger of the opioid crisis was not the drug's toxicity but the marketing that drove the story "addiction risk is low" into the medical field. A company's information provision has the power, beyond the individual prescription, to rewrite the "common sense" of physicians as a whole. That is exactly why information on efficacy and safety must be strictly disciplined — the very reason advertising regulation and material review exist.
Lesson 2 — The gravity of making "addiction and abuse risk" look small
A poorly founded claim of being "hard to get addicted to" justified the mass prescribing of powerful opioids. Understating addiction and abuse risk can bring harm broader and deeper across society than an acute side effect. This crisis shows the weight of conveying risk honestly — especially long-term, social risks like addiction.
Lesson 3 — A drug disaster can chain from a legal product to illicit drugs
Addiction to prescription drugs chained into an epidemic of the illicit drugs heroin and fentanyl. The inappropriate spread of a single medicine can develop into a social problem beyond the frame of medicine. Thinking about a drug's effects only "within the scope of the prescription" is dangerous. A drug acts within society as a whole — that perspective is required.
Lesson 4 — Guard against structural failure with structure
The opioid crisis cannot be explained by one company's misconduct alone. Manufacturing, regulation, and distribution each, in its own place, failed to put on the brakes. Rather than relying on a single point of goodwill or one company's conscience, multilayered checks are required. The layered systems of material review, the duties of the commissioning party, and compliance stand precisely on this idea of "guarding with structure."
07Connections to other chapters
The opioid crisis connects to other chapters of this site as follows.
- Drug Disasters 09 (Vioxx) — sits alongside it as a modern drug disaster in which a company's handling of information (disclosure, marketing) governed the scale of harm
- Advertising Regulation — the core of regulation that disciplines marketing's power to remake prescribing norms
- Material Review — the importance of the work that stops risk-minimizing expressions before they reach the world
- Ethics, Part 1 — a case where the tension between profit and medicine appeared in its most extreme form
The opioid crisis began not with a toxic contaminant or a tainted material, but with the marketing that drove the story "addiction risk is low" into the medical field. Many of the victims were ordinary patients who fell into addiction starting from a drug prescribed by a doctor for post-surgical or chronic pain. What began as treatment chained into addiction, into illicit drugs, and into hundreds of thousands of deaths.
This crisis shows that a drug disaster arises not only from a drug's toxicity but from the handling of information, and not from one company's wrongdoing but from a structure woven by company, regulator, and distributor. So the response, too, cannot keep pace through a single point of conscience — only through multilayered checks.
And above all, this drug disaster is not yet over. Even as settlement money piles up, the crisis is still killing people. What a single phrase that makes risk look small, a single sentence that understates addiction, can cause at the scale of a society — the opioid crisis stands as a present-tense warning before everyone involved in pharma.